Concord Biotech IPO will open for subscription from 04 August 2023. the company aims for an issue size of ₹1,551 Cr through this IPO.
Company Overview
| Full name | Concord Biotech Limited |
| Sector | Healthcare |
| Industry | Pharmaceuticals and Drugs |
| Company Website | https://www.concordbiotech.com/ |
About Company
Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology, supplying 200 customers in over 70 countries including regulated markets, such as the United States, Europe and Japan, and India.
As of 31 March 2022, Concord Biotech had six fermentation-based immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus. It had a total annual installed fermentation capacity for APIs of 1,250 m3 cubic meters. It has established two DSIR (Department of Science & Industrial Research)-approved R&D units with 163 members. The company operates three manufacturing facilities in Gujarat, India, comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera.
The Objective of the Issue
- Achieve the benefits of listing the Equity Shares on the Stock Exchanges and
- Carry out the Offer for Sale of up to 20,925,652 Equity Shares by the Selling Shareholder.
IPO Timetable
| IPO Opening date | 04 August 2023 |
| IPO Closing | 08 August 2023 |
| Basis of Allotment | 11 August 2023 |
| Initiation Refund | 14 August 2023 |
| Credit to Demat Account | 17 August 2023 |
| Listing Date | 18 August 2023 |
IPO details
| Issue type | Book Built Issue IPO |
| IPO issue size | ₹1,551 Cr – 20,925,652 shares |
| Fresh Issue | Nil |
| Offer for sale | ₹1,551 Cr – 20,925,652 shares |
| Face value | ₹01 per share |
| Price Band | ₹705 to ₹741 per share |
| Lot size | 20 Shares |
| Employee Discount | ₹70 per share |
| Listing Exchange | BSE & NSE |
IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 20 | ₹14,820 |
| Retail (Max) | 13 | 260 | ₹192,660 |
| S-HNI (Min) | 14 | 280 | ₹207,480 |
| S-HNI (Max) | 67 | 1,340 | ₹992,940 |
| B-HNI (Min) | 68 | 1,360 | ₹1,007,760 |
Reservation Details
| QIB Shares Offered | 50% |
| NII (HNI) Shares Offered | 15% |
| Retail Shares Offered | 35% |
Financial Performance
| FY 2021 | FY 2022 | FY 2023 | |
| Revenue | 616.94 | 712.93 | 853.17 |
| Expenses | 317.58 | 495.19 | 568.42 |
| Net income | 234.89 | 174.93 | 240.08 |
| Margin (%) | 38.07 | 24.54 | 28.14 |
Valuations & Margins
| FY 2021 | FY 2022 | FY 2023 | |
| EPS | 22.45 | 16.72 | 22.95 |
| PE ratio | – | – | 30.72 – 32.29 |
| RONW (%) | 26.55 | 16.64 | 20.06 |
| NAV | 95.53 | 105.45 | 123.31 |
| ROCE (%) | 28.54 | 20.55 | 24.27 |
| EBITDA (%) | 53.02 | 37.82 | 40.47 |
| Debt/Equity | 0.09 | 0.05 | 0.02 |
Company Promoters
- Sudhir Vaid
- Ankur Vaid
Promoter Holding
| Pre Issue Share Holding | – |
| Post Issue Share Holding | – |
Lead Manager(s)
- Kotak Mahindra Capital Company Limited
- Citigroup Global Markets India Private Limited
- Jefferies India Private Limited
IPO Registrar
LINK INTIME INDIA PRIVATE LIMITED
C-101, 1st Floor, 247 Park, L.B.S. Marg,
Vikhroli (West), Mumbai – 400083, Maharashtra
Phone: +91 22 49186200
E-mail: concordbiotech.ipo@linkintime.co.in
Website: www.linkintime.co.in
Contact Details
CONCORD BIOTECH LIMITED
16th floor, B-Wing, Mondeal Heights,
Iscon Cross Road, S.G. Highway, Ahmedabad – 380015
Phone: 079-6813 8700
Email: complianceofficer@concordbiotech.com
Website: www.concordbiotech.com
Allotment Status
Concord Biotech IPO allotment will be available on Link Intime’s website. Click on this link to get allotment status.
Final thoughts
Concord Biotech IPO is going to hit Dalal Street soon. applying for an IPO is purely a personal choice. study well about the company and do subscribe if you are feeling good about the company. I hope this post will give you enough details to make a fundamental study of the company. learn well and make wise decisions.
Happy Investing
